Skip to main content
. 2019 Feb 12;17(3):375–386. doi: 10.5217/ir.2018.00141

Fig. 2.

Fig. 2.

Patient disposition. aThe 3 patients who discontinued the double-blind (DB) period all completed the safety follow-up (SF) period. OL, open-label; AE, adverse event.